A5016193776- Monoclonal and Polyclonal Antibodies Research
- Pharmacological Effects of Natural Compounds
- Growth Hormone and Insulin-like Growth Factors
- Autophagy in Disease and Therapy
- Muscle Physiology and Disorders
- Biosimilars and Bioanalytical Methods
- Pituitary Gland Disorders and Treatments
- Adenosine and Purinergic Signaling
- Biochemical and Molecular Research
- CAR-T cell therapy research
- Protein purification and stability
- Congenital Diaphragmatic Hernia Studies
- Adolescent and Pediatric Healthcare
- RNA modifications and cancer
- Cancer-related gene regulation
- Chronic Lymphocytic Leukemia Research
- Nutrition and Health in Aging
Pusan National University
2025
The Ohio State University
1982-2025
ABSTRACT Background Cancer cachexia is a debilitating syndrome characterized by irreversible losses in skeletal muscle mass, with or without adipose tissue. an underrecognized that impacts ~50% of all cancer patients and accounts for up to ~20% deaths. Lung remains one the deadliest cancers United States estimated 137 000 deaths year 2021 alone. highly comorbid cachexia. Pre‐clinical models are heavily relied upon study both lung cachexia; however, there need develop novel relationship...
Objectives: Higher catabolic clearance (CL) of immune checkpoint inhibitors (ICIs) is a biomarker for less favorable outcomes, independent drug exposure, in patients with cancer, thus leading to confounded exposure-response relationships. Patients rapid mAb CL present cancer cachexia phenotypes[1,2], though underlying mechanisms linking high CL, poor response, and are poorly understood. Our previous research demonstrates elevated ICIs can be replicated mouse models cachexia, the increased...
Background: HOSU-53 (JBZ-001), an orally bioavailable new chemical entity, represents a highly potent dihydroorotate dehydrogenase (DHODH) inhibitor in late preclinical development for application cancer therapy. Methods: Multiple Good Laboratory Practice (GLP) and non-GLP studies were conducted mice, rats, dogs. Plasma samples of (DHO), the substrate DHODH, collected pharmacokinetic (PK) pharmacodynamic (PD) assessment modeling. Two modeling approaches utilized to understand PK/PD...
Haloperidol, in concentrations excess of 10(-5)M promotes the release prolactin from rat anterior pituitary cells monolayer culture. Histologic evidence revealed that 10(-4)M cause an irreversible cytotoxic effect resulted a loss cell membrane integrity and massive intracellular into surrounding medium. Paradoxically, at 10(-5)M, haloperidol significantly inhibited promoted accumulation secretory granules. Lower had no significant effect. Although it is nominally classified as dopamine...